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Abstract
Introduction Distinguishing pulmonary edema due to acute lung
injury (ALI) or the acute respiratory distress syndrome (ARDS)
from hydrostatic or cardiogenic edema is challenging in critically
ill patients. B-type natriuretic peptide (BNP) can effectively
identify congestive heart failure in the emergency room setting
but, despite increasing use, its diagnostic utility has not been
validated in the intensive care unit (ICU).
Methods We performed a prospective, blinded cohort study in
the medical and surgical ICUs at the University of Chicago
Hospitals. Patients were eligible if they were admitted to the ICU
with respiratory distress, bilateral pulmonary edema and a
central venous catheter suggesting either high-pressure
(cardiogenic) or low-pressure (ALI/ARDS) pulmonary edema.
BNP levels were measured within 48 hours of ICU admission
and development of pulmonary edema and onward up to three
consecutive days. All levels were drawn simultaneously with the
measurement of right atrial or pulmonary artery wedge pressure.
The etiology of pulmonary edema – cardiogenic or ALI/ARDS –
was determined by three intensivists blinded to BNP levels.
Results We enrolled a total of 54 patients (33 with ALI/ARDS
and 21 with cardiogenic edema). BNP levels were lower in
patients with ALI/ARDS than in those with cardiogenic edema
(496 ± 439 versus 747 ± 476 pg/ml, P = 0.05). At an accepted
cutoff of 100 pg/ml, specificity for the diagnosis of ALI/ARDS
was high (95.2%) but sensitivity was poor (27.3%). Cutoffs at
higher BNP levels improved sensitivity at considerable cost to
specificity. Invasive measures of filling pressures correlated
poorly with initial BNP levels and subsequent day BNP values
fluctuated unpredictably and without correlation with
hemodynamic changes and net fluid balance.
Conclusion BNP levels drawn within 48 hours of admission to
the ICU do not reliably distinguish ALI/ARDS from cardiogenic
edema, do not correlate with invasive hemodynamic
measurements, and do not track predictably with changes in
volume status on consecutive daily measurements.
Introduction
Early implementation of a lung protective ventilation strategy
can improve survival from acute lung injury and the acute res-
piratory distress syndrome (ALI/ARDS) [1]. However, a recent
survey of intensive care units (ICUs) found that a lack of phy-
sician recognition of ALI/ARDS was a major barrier to the ini-
tiation of lung-protective ventilation [2]. Attributing pulmonary
edema to volume overload or congestive heart failure may
explain some of this underdiagnosis. The American–European
Consensus Conference definition of ALI/ARDS requires the
exclusion of left atrial hypertension [3]. However, advanced
age and comorbidities can make this difficult in critically ill
ALI = acute lung injury; ARDS = acute respiratory distress syndrome; AUC = area under curve; BNP = B-type natriuretic peptide; CHF = congestive 
heart failure; ICU = intensive care unit; LVD = left ventricular dysfunction; PCWP = pulmonary capillary wedge pressure; RAP = right atrial pressure; 
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patients. Pulmonary artery catheters reliably measure left atrial
pressure, but placement can be time-consuming and a recent
multicenter randomized trial found no benefit with their routine
use in ALI/ARDS [4]. Echocardiography provides noninvasive
assessment of left ventricular dysfunction but requires an
experienced operator and is limited by lack of universal acces-
sibility and added cost.
B-type natriuretic peptide (BNP), a rapidly-assayed, serum
biomarker, has been found to be effective in distinguishing
congestive heart failure (CHF) from other causes of dyspnea
in the emergency or urgent care setting [5-7]. Ease, low cost,
and objectivity have led to widespread incorporation of BNP
into the clinical evaluation of CHF. Anecdotal experience also
suggests an increasing use of BNP by physicians in the ICU;
however, although extrapolation to other clinical settings is
tempting, appropriate validation is lacking.
Jefic and colleagues found that levels of BNP correlated with
severity of left ventricular dysfunction but did not reliably dis-
tinguish high from low pulmonary capillary wedge pressure
(PCWP) causes of respiratory failure in critically ill patients [8].
In addition, BNP levels can be markedly, but similarly,
increased in both cardiogenic and septic shock despite signif-
icant differences in hemodynamic measures [9-11]. Con-
versely, Rana and colleagues found that a BNP level of less
than 250 pg/ml had a high specificity for ALI/ARDS and was
comparable to measuring PCWP and superior to troponin lev-
els and echocardiography for distinguishing between ALI/
ARDS and cardiogenic edema [12].
There are many possible explanations for these discrepancies.
Coexisting cardiac and other organ dysfunction, rapid
changes in volume status, variable bioavailability [13] and
burst synthesis of BNP [14,15] may all confound interpretation
of BNP levels in critically ill patients. Given the potential for
confounding by coexisting or overlapping conditions of lung
injury and hydrostatic pulmonary edema, we performed a pro-
spective clinical trial of the diagnostic utility of BNP in selected




This prospective, blinded cohort study was approved by the
Institutional Review Board and performed in the medical and
surgical ICUs at the University of Chicago Hospitals. Patients
were eligible for enrollment on the following criteria: if they
were admitted to an ICU; if they had a chest radiograph con-
sistent with bilateral pulmonary edema on the morning of
enrollment, if they had a partial pressure of arterial oxygen/frac-
tion of inspired oxygen (PaO2/FiO2) ratio of less than 300; and
if they had a pulmonary artery catheter or a central venous
catheter and current echocardiogram. Enrollment and first
BNP sampling were required within 48 hours of the first qual-
ifying chest radiograph performed in an ICU.
To aid in definitive classification, only patients identified during
screening by a study physician as having clear clinical evi-
dence of high-pressure (cardiogenic) or low-pressure (ALI/
ARDS) pulmonary edema were enrolled, with the exclusion of
ambiguous, intermediate cases. In addition to clinical history,
enrollment to the cardiogenic edema cohort required either (1)
a PCWP of more than 20 mmHg or (2) a right atrial pressure
(RAP) of more than 14 mmHg with a current echocardiogram
documenting (on final report by readers blinded to patient's
study classification and BNP level) new or worsening left ven-
tricular systolic or diastolic dysfunction (LVD). Echocardio-
grams were required during the current admission up to
enrollment. LVD was considered 'new' in patients without a
previous history of CHF or with a previous echocardiogram
documenting normal left ventricular function and 'worsened'
only when a previous echocardiogram was available for direct
comparison. Conversely, enrollment to the ALI/ARDS cohort
required a PCWP of less than 16 mmHg or a RAP of less than
10 mmHg and no echocardiographic evidence of new or
worsening LVD. Invasive hemodynamic pressure tracings
were recorded simultaneously with blood sampling for BNP
levels. Readings were taken at end-expiration using airway
pressure waveform tracings as recommended by the ARDS
Clinical Trials Network [4].
Final classification as ALI/ARDS or cardiogenic edema was
done independently by a jury of three experienced critical care
attending physicians blinded to BNP results and to the
patient's enrollment cohort. Jurors reviewed information on
clinical course and response to treatment up to discharge in
addition to daily waveform tracings of invasive pressure meas-
urements, echocardiogram reports, and chest radiographs.
Discrepant cases were classified by majority opinion.
Patients with renal failure requiring dialysis, patients with
intracranial hemorrhage or elevated intracranial pressure,
patients with a history of cardiac surgery within 2 months,
patients on a nesiritide infusion, pregnant women, and patients
with persistent symptoms for greater than 2 weeks before
admission were excluded.
Procedures
Informed consent was obtained from each patient or surrogate
decision maker. Baseline characteristics that were collected
included the following: patient demographics, serum creati-
nine, Acute Physiology and Chronic Health Evaluation II
(APACHE II) severity of illness score [16], lung injury score
[17], requirement for vasoactive drugs (dobutamine, milrinone,
vasopressin, norepinephrine, or dopamine) at the time of blood
draw on day 1, and need for mechanical ventilation (noninva-
sive positive pressure ventilation or mechanical ventilation by
means of an endotracheal tube or tracheostomy). A presenceAvailable online http://ccforum.com/content/12/1/R3
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of right heart dysfunction was defined as a mean pulmonary
artery pressure of more than 20 mmHg or echocardiographic
evidence of mild or worsening pulmonary hypertension with
right ventricular dysfunction or dilatation [18].
Measurement of BNP occurred immediately after enrollment
(within 48 hours of qualifying chest radiograph and ICU admis-
sion) and then daily for a total of 3 days. Subsequent samples
were not available for patients who were transferred from the
ICU, who had discontinuation of invasive venous monitoring or
who were started on dialysis or a nesiritide infusion during the
3-day study period. Waveform tracings from central venous
and pulmonary artery catheters were recorded simultaneously
with the time of blood draws. Blood samples were collected in
tubes containing potassium EDTA and were measured with a
rapid fluorescence immunoassay (Triage; Biosite Diagnostics,
San Diego, CA, USA) [5,6].
Statistical analysis
Data were analysed with GraphPad Prism (GraphPad, San
Diego, CA, USA) software. A Student's t test or Mann–Whit-
ney U test was used to assess differences between continu-
ous variables as appropriate. Dichotomous, categorical
variables were analyzed by Fisher exact or χ2 tests. Correlation
between continuous variables was assessed by Pearson cor-
relation coefficients. Data are presented as means ± standard
deviations and medians with interquartile ranges where appro-
priate. Despite a positive skew in distribution of BNP levels,
similar results were found between analyses of log-trans-
formed and raw BNP values, and only comparisons of raw
BNP values are reported. Receiver operating characteristic
(ROC) curves generated by Analyse-It Clinical Laboratory
(Leeds, UK) were used to assess the utility of BNP as a diag-
nostic tool.
Results
Fifty-four patients were enrolled in the study. On completion of
adjudication by the three intensivists, 21 and 33 patients were
classified as cardiogenic and ALI/ARDS, respectively. Base-
line characteristics of cardiogenic and ALI/ARDS groups are
presented in Table 1. There were no significant differences in
Table 1
Baseline characteristics and invasive hemodynamics by edema classification
Characteristic ALI/ARDS CHF P
n 33 21
Age, yr 60 ± 3 59 ± 5 0.81
Female sex, n (percentage) 21 (64) 10 (48) 0.25
Weight (kg) 74.7 ± 4.9 91.7 ± 6.8 0.04
Race, n (percentage)
Black 16 (48) 10 (48)
Caucasian 16 (48) 11 (52) 0.67
Hispanic, non-black 1 (4) 0 (0)
APACHE II score 20.7 ± 1.1 20.2 ± 1.2 0.77
Lung injury score 2.6 ± 0.1 2.6 ± 0.2 1.0
Creatinine, mg/dl 1.2 ± 0.1 2.2 ± 0.3 <0.01
Vasoactive druga use, n 
(percentage)
15 (45) 11 (52) 0.25
Mechanical ventilation, n 
(percentage)
24 (72) 11 (52) 0.13
RHDb, n (percentage) 16 (48) 15 (71) 0.10
LVDc, n (percentage) 4 (12) 20 (95) <0.01
RAP, mmHg 5.9 ± 6.3 15.2 ± 5.7 <0.0001
PCWP, mmHg (n = 5 and 9) 6.8 ± 2.5 21.4 ± 5.5 <0.0001
ALI, acute lung injury; ARDS, acute respiratory distress syndrome; CHF, congestive heart failure; APACHE II, Acute Physiology and Chronic 
Health Evaluation II severity of illness; RAP, right atrial pressure; PCWP, pulmonary capillary wedge pressure. Where errors are shown, results are 
means ± SD.
aVasoactive drugs include dobutamine, milrinone, norepinephrine, phenylephrine, vasopressin or dopamine; bechocardiographic evidence of right 
ventricular dilatation, dysfunction and/or pulmonary hypertension or pulmonary artery catheter readings of mean pulmonary artery pressure ≥ 20 
mmHg;cechocardiographic evidence of left ventricular dysfunction.Critical Care    Vol 12 No 1    Levitt et al.
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age, sex, race, lung injury score, frequency of right heart dys-
function or need for mechanical ventilation. Mean weight and
serum creatinine levels were higher in the cardiogenic edema
cohort. LVD was present in 20 of 21 (one patient met PCWP
criteria without echocardiographic evidence of LVD) patients
with cardiogenic edema. Four patients with ALI/ARDS had
LVD that was deemed stable (two patients) or slightly
improved (two patients) by echocardiography. None of these
four patients had an increased RAP or PCWP. Mean RAP (5.9
± 6.3 versus 15.2 ± 5.7 mmHg, P < 0.0001) and PCWP (6.8
± 2.5 versus 21.4 ± 5.5 mmHg, p < 0.0001) were significantly
lower in the ALI/ARDS cohort.
Jury decisions were unanimous in 50 of 54 cases (92.6%).
The remaining four judgments made on majority rule were split
evenly between CHF and ALI/ARDS groups, so that 31 of 33
(93.9%) ALI/ARDS and 19 of 21 (90.5%) CHF cases were
judged unanimously. Baseline BNP levels (median [interquar-
tile range]) were higher in patients with cardiogenic edema
(600 pg/ml [352 to 1,300] versus 369 pg/ml [87 to 709], P =
0.045) (Figure 1). There was no difference in BNP values
between patients with ALI (n = 15) and ARDS (n = 18) (398
pg/ml [344 to 782] versus 202 pg/ml [68 to 657], P = 0.15).
The utility of BNP measurements in distinguishing ALI/ARDS
(disease positive) from cardiogenic edema (disease negative)
was assessed with the ROC curve analysis (Figure 2). The
area under the curve (AUC) is 0.67 (95% confidence interval
0.52 to 0.81). Using a cutoff of BNP < 100 pg/ml (established
in emergency department patients) [5-7] to diagnose ALI/
ARDS, the specificity was 95.2% but the sensitivity was only
27.3%. Given the slightly greater prevalence of ALI/ARDS in
our cohort, there were actually more ALI/ARDS patients with
BNP values above this cutoff (false negatives) than cardio-
genic edema patients (true negatives). At a cutoff of less than
250 pg/ml (suggested by Rana and colleagues [12]), specifi-
city and sensitivity were 76.2% and 33.3%, respectively.
Higher cutoff levels improved sensitivity but at considerable
cost to specificity (Figure 2).
Results of subgroup analyses are summarized in Table 2.
Exclusion of patients with a serum creatinine greater than 3.0
mg/dl slightly increased the difference in mean BNP values
between the cardiogenic and ALI/ARDS groups and the AUC
of the corresponding ROC curve (0.67 to 0.70). Conversely,
separate evaluation excluding the four ALI/ARDS patients with
evidence of LVD and the four patients who did not receive
unanimous adjudication decreased differences in mean BNP
values between ALI/ARDS and cardiogenic edema groups
and had no effect on the AUC of the corresponding ROC
curves.
Correlations of invasive measurements of filling pressures
(RAP and PCWP) with BNP levels are shown in Figure 3. A
significant relationship exists between RAP and BNP, but the
correlation is poor (R2 = 0.11). In addition, no significant rela-
tionship was found between changes in subsequent day BNP
levels and the associated change in RAP or PCWP (Figure 3).
Serial measurements of BNP revealed no significant
Figure 1
Dot-plot of initial B-type natriuretic peptide value classified by edema  type Dot-plot of initial B-type natriuretic peptide value classified by edema 
type. Bold line and whiskers represent mean and ± 1 standard devia-
tion. *, P = 0.05 for the difference in B-type natriuretic peptide (BNP) 
levels between patients with acute lung injury/acute respiratory distress 
syndrome (ALI/ARDS) and patients with congestive heart failure. There 
is no difference between patients with ALI and patients with ARDS (P 
= 0.47).
Figure 2
Receiver operating characteristics of the diagnostic utility of B-type  natriuretic peptide Receiver operating characteristics of the diagnostic utility of B-type 
natriuretic peptide. True positives are patients with acute lung injury/
acute respiratory distress syndrome, and true negatives are patients 
with congestive heart failure. Area under curve = 0.67 (95% confi-
dence interval 0.52 to 0.81). The table provides the corresponding sen-
sitivity, specificity, predictive values and likelihood ratios of 
representative B-type natriuretic peptide (BNP) values.Available online http://ccforum.com/content/12/1/R3
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difference in either the direction (number of subjects whose
BNP value increased versus decreased) or the magnitude of
change (mean change in each edema class) in BNP levels
between the ALI/ARDS and cardiogenic groups (Table 3).
Finally, changes in BNP levels did not correlate with net fluid
balance for the previous 24 hours.
Discussion
In this prospective, blinded cohort study, we found that BNP
levels did not reliably distinguish ALI/ARDS from cardiogenic
causes of pulmonary edema despite efforts to exclude patients
with possible overlapping conditions. In addition, BNP levels
correlated poorly with simultaneous invasive measures of RAP
and PCWP. Serial measurements over a 3-day period did not
improve performance because changes in BNP levels did not
correlate with changes in invasive measures of filling pres-
sures and did not differ in direction or magnitude between
patients with ALI/ARDS and those with cardiogenic edema.
Our results are similar to those of other investigators who
found that BNP levels did not discriminate between cardio-
genic and septic shock [9-11] and between high and low
PCWP causes of pulmonary edema [8]. This may be due to
increased levels of BNP related to myocardial dysfunction of
sepsis or direct effect of inflammatory mediators on myocytes
[19,20]. In addition, BNP levels are known to be elevated in
ARDS, in part as a result of acute right heart dysfunction
[21,22]. Right heart dysfunction was a common occurrence in
our cohort (48% and 71% of the ALI/ARDS and CHF cohorts,
respectively). Increased stretch of the right ventricle and right
atrium may be a source of BNP release in critically ill patients,
independently of left ventricular filling pressures. In addition, in
the previous studies of shock, there were significant differ-
ences in PCWP values between cardiac and non-cardiac eti-
ologies; however, the 'low' PCWP values were markedly
abnormal (means of 16 ± 4 and 18 ± 7 mmHg, respectively)
[10,11].
We sought to avoid this confounder by including only ALI/
ARDS patients with a PCWP of less than 16 mmHg and car-
diogenic edema patients with a PCWP of more than 20
mmHg. In our study, mean RAP and PCWP were 5.9 ± 5.7
and 6.8 ± 2.5 mmHg, respectively, in the ALI/ARDS patients,
in contrast with 15.2 ± 5.7 and 21.4 ± 5.5 mmHg in the CHF
Table 2
Mean BNP values and receiver operating characteristic analysis by subgroup
Patients n BNPb (pg/ml) P AUC
ALI/ARDS CHF ALI/ARDS CHF
All 33 21 369 (87–709) 600 (352–1,300) 0.04 0.67 (0.52–0.81)
Serum creatinine < 3.0 mg/dl 32 16 359 (86–665) 653 (419–1,300) 0.02 0.70 (0.55–0.86)
Unanimous jury 31 19 369 (86–665) 653 (419–1,300) 0.05 0.67 (0.52–0.82)
Excluding the four ALI/ARDS with LVDa 29 21 394 (87–864) 600 (352–1,300 0.06 0.67 (0.52–0.82)
BNP, B-type natriuretic peptide; ALI, acute lung injury; ARDS, acute respiratory distress syndrome; CHF, congestive heart failure; AUC, area 
under curve. P values are for comparisons of BNP values between ALI/ARDS and CHF patients.
aLeft ventricular dysfunction on recent echocardiogram (stable or improved in all four patients); bmedian (interquartile range).
Table 3
Serial BNP measurements by edema classification
Period Direction of BNP change n (ΔBNP, pg/ml) P
ALI/ARDS CHF
Days 1 to 2 Increase 17 (254 ± 302) 5 (228 ± 287)
Decrease 9 (-246 ± 178) 8 (-252 ± 208) 0.17b
Alla 26 (73 ± 339) 17 (-52 ± 290) 0.21c
Days 2 to 3 Increase 9 (143 ± 200) 5 (396 ± 132)
Decrease 11 (-191 ± 187) 7 (-160 ± 142) 1.0b
Alla 24 (-34 ± 231) 15 (57 ± 281) 0.28c
BNP, B-type natriuretic peptide; ALI, acute lung injury; ARDS, acute respiratory distress syndrome; CHF, congestive heart failure. The table shows 
an analysis of changes in BNP levels in direction (increase or decrease) and magnitude (ΔBNP) from day 1 to day 2 and from day 2 to day 3, 
classified by edema type. Where errors are shown, results are means ± SD.
aValues for some patients remained above the upper limit of the assay (1,300 pg/ml) and were consider unchanged. bχ2 comparing the proportion 
of subjects with an increase in BNP by edema type; ct test of magnitude of BNP change by edema type.Critical Care    Vol 12 No 1    Levitt et al.
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patients. However, this wide separation in filling pressures
between cohorts did not improve the discriminatory function of
BNP in our study.
We did not specifically study the presence or impact of left
ventricular diastolic dysfunction in our cohorts. Given the low
prevalence of pulmonary artery catheters in our ALI/ARDS
patients (5 of 33), it is possible that our some of our ALI/ARDS
patients with high BNP levels were actually misclassified
because of under-recognition of diastolic dysfunction and
occult left atrial hypertension. However, all patients without a
pulmonary artery catheter required a current echocardiogram
to be eligible for enrollment. We believe that our reference
standard for edema classification – independent adjudication
by three blinded experienced intensivists on retrospective
review of all relevant data (including echocardiogram reports,
chest radiographs, invasive pressure tracings and response to
therapy) – although imperfect, is the most valid and clinically
relevant standard available. Similar reference standards have
been used by Maisel and colleagues [5], in their landmark
Figure 3
Correlation between B-type natriuretic peptide values and invasive hemodynamic measurements Correlation between B-type natriuretic peptide values and invasive hemodynamic measurements. (a) Baseline B-type natriuretic peptide (BNP) and 
right atrial pressure (RAP) values. (b) Baseline BNP and pulmonary capillary wedge pressure (PCWP) values. (c) Change in BNP and RAP values 
(ΔBNP and ΔRAP, respectively) between day 1 and day 2. (d) Change in BNP and PCWP values (ΔBNP and ΔPCWP, respectively) between day 1 
and day 2.Available online http://ccforum.com/content/12/1/R3
Page 7 of 9
(page number not for citation purposes)
paper demonstrating the utility of BNP for diagnosing heart
failure in the emergency room, and by Rana and colleagues
[12].
Rana and colleagues, using methodology similar to ours to
evaluate the utility of BNP in distinguishing patients with ALI
from patients with CHF, found the AUC of their ROC to be
0.71 [12]. Using a BNP level of less than 250 pg/ml to diag-
nose ALI/ARDS had good specificity (90%) and modest sen-
sitivity (40%), with positive and negative likelihood ratios of 4.0
and 0.67, respectively. When restricted to patients without
renal insufficiency (41% of their cohort) the AUC improved to
0.82. When limited to patients without renal insufficiency and
ALI/ARDS patients without concomitant cardiac dysfunction
(only 25% of their total cohort), the AUC improved to 0.86. In
contrast, our study, which by design excluded ALI patients
with coexisting cardiac dysfunction, found an AUC of 0.67,
and excluding patients with a serum creatinine of more than
3.0 mg/dl had a minimal impact on performance (AUC 0.70).
However, serum creatinine may not always accurately reflect
creatinine clearance, and excluding patients on the basis of a
more sensitive measure of renal dysfunction (such as a creat-
inine clearance of less than 60 ml/min, as used by Rana and
colleagues [12]) might have improved the performance of
BNP in our study.
Serum creatinine and weight were significantly greater in the
cardiogenic edema cohort and may have biased our findings.
However, by multivariate linear regression (modeling BNP lev-
els on edema type, weight, and creatinine) there was a trend
toward a positive association of BNP and creatinine (P = 0.09)
and a negative association of weight and BNP (P = 0.08) but
no association of BNP and edema type (P = 0.61), suggesting
that these confounders do not explain the poor diagnostic util-
ity of BNP in our study (data not shown). The median time from
recognition of pulmonary edema to measuring BNP levels was
3 hours (interquartile range 0.5 to 14) in the study by Rana and
colleagues. We did not specifically record time to BNP draw,
but our protocol allowed enrollment up to 48 hours after the
presence of a qualifying chest radiograph and ICU admission.
Importantly, while we allowed up to 48 hours for enrollment
and first blood draw, all BNP and hemodynamic measure-
ments were made simultaneously. This protocol difference
probably accounts for the better performance in the Rana
study. Similarly, other authors have found excellent sensitivity
and specificity for the diagnosis of CHF when BNP is tested
on presentation to the emergency department [5-7]. Our data
suggest that the potential complex interactions of intensive
therapy (such as rapid changes in volume status, vasoactive
medications, and positive pressure ventilation) may rapidly
decay the diagnostic utility of BNP in the ICU. Diagnostic utility
limited to the immediate presentation to the ICU may not be
useful in many clinical settings.
In addition, despite a specificity of 90% for the diagnosis of
ALI/ARDS at a cutoff of 250 pg/ml in the Rana study, those
authors conclude that no level of BNP adequately ruled out a
diagnosis of cardiogenic edema. Similarly, the authors sug-
gested a BNP of more than 950 pg/ml as a threshold for diag-
nosing cardiogenic edema (positive likelihood 3.1 and
negative likelihood of 0.7), leaving a large range of intermedi-
ate values (between 250 and 950 pg/ml) without diagnostic
utility. We found 90% specificity for ALI/ARDS at a BNP of
157 or less; however, the corresponding sensitivity was only
30%, resulting in a positive likelihood ratio of 3.2 but a nega-
tive likelihood ratio of only 0.77. Higher levels of BNP showed
improved sensitivity but at considerable cost to specificity.
Even a BNP level of 1,000 pg/ml provided only modest (79%)
sensitivity for diagnosing ALI/ARDS. Applying either of these
upper (950 or 1,000 pg/ml) and lower (157 or 250 pg/ml) cut-
offs to our cohort would result in 40 to 50% of test results fall-
ing in an intermediate and non-diagnostic range.
In our study, serial measurements of BNP did not correlate
with day-to-day changes in invasive measures of filling pres-
sures or net fluid balance. Recent clinical trials have shown
improved clinical outcomes in patients with ALI/ARDS, with
fluid management strategies targeting lower filling pressures
or a negative fluid balance [23,24]. Our data suggest that
BNP measurements will not be useful for monitoring the
effects of fluid management strategies in ICU patients.
Our study has several limitations. First, it is limited to a rela-
tively small sample size at a single center. However, given the
significant overlap in BNP levels between cohorts, it is not
likely that a larger sample would significantly affect our results.
We found an ROC curve with an AUC of 0.67 (95% confi-
dence interval 0.52 to 0.82). Doubling our sample size to 104
patients, while maintaining the same ratio of ALI/ARDS to CHF
patients, would probably have had little effect, because the
95% confidence interval of the AUC would only narrow to
0.57 to 0.77. Second, we present a correlation between BNP
levels and invasive measures of filling pressures. In critically ill
patients with the potential for increased pleural pressures, fill-
ing pressures may not be reliable surrogates for cardiac vol-
umes. Finally, despite our best efforts to eliminate coexisting
cases of ALI/ARDS and CHF, at least some degree of overlap
is suggested by the less than 100% (50 of 54 patients) agree-
ment on final classification by experienced intensivists. How-
ever, as the results of the recent ARDS Network study of fluid
management in ALI/ARDS suggest, this dilemma is likely to be
even more prevalent in clinical practice [23]. In that trial,
despite standard consensus inclusion and exclusion criteria,
30% of patients enrolled with ALI/ARDS had a PCWP of more
than 18 mmHg at initial placement of a pulmonary artery
catheter. More importantly, this study found a shorter duration
of mechanical ventilation and ICU stay with a conservative fluid
strategy, suggesting that some degree of hydrostatic edema is
present in many cases of ALI/ARDS. These results suggestCritical Care    Vol 12 No 1    Levitt et al.
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that a clear distinction between ALI/ARDS and cardiogenic
edema is not likely with any diagnostic modality and may not
be clinically relevant with regard to fluid management.
However, early recognition of ALI/ARDS remains important in
improving clinician compliance with lung protective ventilation
and in the diagnosis and treatment of underlying etiologies.
Unfortunately, an increased use of BNP levels in the ICU is not
likely to assist clinicians in this regard.
Conclusion
In our study, BNP testing within 48 hours of recognition of pul-
monary edema and ICU admission did not reliably distinguish
ALI/ARDS from cardiogenic pulmonary edema. This failure
occurred despite efforts to exclude patients with coexisting
conditions. Applying cutoff values at the low and high ends of
the spectrum provided some utility in diagnosing ALI/ARDS
and cardiogenic edema, respectively, but left many results in
an intermediate and non-diagnostic range. Overlapping cases
of ALI/ARDS and cardiac dysfunction are common in critically
ill patients and will probably limit the clinical utility of BNP test-
ing in this setting. In addition, serial sampling of BNP levels did
not correlate with changes in invasive measures of filling pres-
sure or net fluid balance, suggesting little role for use in moni-
toring effects of therapy.
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